資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34445
|
| 標題: | Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients |
| 作者: | Huang, Yu-Shan
Cheng, Chien-Yu
Liou, Bo-Huang
Lu, Po-Liang
Cheng, Shu-Hsing
Lee, Yuan-Ti
Liu, Chun-Eng
Sun, Hsin-Yun
Yang, Chia-Jui
Tang, Hung-Jen
Lin, Shih-Ping
Ho, Mao-Wang
Huang, Sung-Hsi
Tsai, Hung-Chin
Lee, Chen-Hsiang
Hung, Chien-Ching |
| 貢獻者: | Natl Taiwan Univ Hosp, Dept Internal Med
Natl Taiwan Univ, Coll Med
Taoyuan Gen Hosp, Dept Infect Dis, Minist Hlth & Welf
Natl Yang Ming Univ, Sch Publ Hlth
Hsinchu MacKay Mem Hosp, Dept Internal Med
Kaohsiung Med Univ Hosp, Dept Internal Med
Kaohsiung Med Univ, Coll Med
Taipei Med Univ, Sch Publ Hlth
Chung Shan Med Univ Hosp, Dept Internal Med
Chung Shan Med Univ, Sch Med
Changhua Christian Hosp, Dept Internal Med
Natl Yang Ming Univ, Sch Med
Far Eastern Mem Hosp, Dept Internal Med
Chi Mei Med Ctr, Dept Internal Med, Tainan, Taiwan;[Tang, Hung-Jen
Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
Taichung Vet Gen Hosp, Dept Internal Med
China Med Univ Hosp, Dept Internal Med
Natl Taiwan Univ Hosp, Dept Internal Med, Hsin Chu Branch
Natl Taiwan Univ, Dept Trop Med & Parasitol, Coll Med
Kaohsiung Vet Gen Hosp, Dept Internal Med
Kaohsiung Chang Gung Mem Hosp, Dept Internal Med
Chang Gung Univ, Coll Med |
| 關鍵字: | hepatitis B
antiretroviral therapy
proteinuria
bone mineral density |
| 日期: | 2021 |
| 上傳時間: | 2023-11-11 11:53:11 (UTC+8) |
| 出版者: | LIPPINCOTT WILLIAMS & WILKINS |
| 摘要: | Background: The efficacy and safety of switching from tenofovir disoproxil fumarate-based antiretroviral therapy to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has not been widely investigated in HIV/hepatitis B virus (HBV)-coinfected Asian population. Methods: Between February and October 2018, HIV/HBV-coinfected patients who had achieved HIV viral suppression with tenofovir disoproxil fumarate-containing regimens were switched to E/C/F/TAF. Assessments of plasma HBV and HIV viral load, HBV serology, renal function, lipid profiles, and bone mineral density (BMD) were performed at weeks 24 and 48 after switch. Results: A total of 274 HIV/HBV-coinfected participants were enrolled, with 12.8% testing HBeAg-positive and 94.2% having plasma HBV DNA <20 IU/mL at baseline. At weeks 24 and 48, 92.7% and 89.8% achieved plasma HBV DNA <20 IU/mL; 4.7% and 5.1% had HBV DNA >= 20 IU/mL; and 2.6% and 5.1% had no data, respectively. At weeks 24 and 48, 95.6% and 94.2% of participants maintained HIV RNA <50 copies/mL, respectively. Compared with baseline, the median urine beta 2-microglobulin-to-creatinine ratio at week 48 decreased significantly from 165 to 90 mu g/g (P < 0.001). The mean BMD of the spine and hip improved at week 48 (+1.77% and +1.33%, respectively). Significantly higher lipid profiles were observed after switch to E/C/F/TAF. Thirteen (4.7%) patients withdrew from the study before week 48, with 7 (2.6%) patients because of adverse effects. Conclusions: Switch to E/C/F/TAF maintained HBV and HIV viral suppression and resulted in the improvement of proteinuria and BMD of the spine and hip but increased lipid levels in HIV/HBV-coinfected patients at week 48. |
| 關聯: | JAIDS-J ACQ IMM DEF, v.86, n.4, pp.473-481 |
| 顯示於類別: | [保健營養系(所) ] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 203 | 檢視/開啟 | | QAI.0000000000002589.pdf | | 397Kb | Adobe PDF | 100 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
